Pharmatica

In the recent episode of The Clinical Compass podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, is joined by Dr Amber Hill, Founder and CEO of Research Grid. They talk about how pharmaceutical companies and their leaders should approach the use of AI in clinical trials.

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."

In the recent episode of the Digital Pulse podcast, host Shubhangi Dua was joined by Clara Toombs, Founder at Fertilia AI; Caroline Biddle, Founder at Working Through Fertility; and Dr Divpreet Sacha, Neko Health GP, Co-Founder at HHEI (The Hormonal Health Equity Initiative) and Digital Safety Officer.

In this special Scientific Council Spotlight episode of The Discovery Loop podcast, host Shubhangi Dua, Journalist, Podcast Producer and Podcast Host at Pharmatica.io, sits down with Deepankar Nayak, the CEO of Deep Longevity. Nayak also serves on Pharmatica’s Scientific Council.

In the recent episode of The Discovery Loop podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io, sat down with Diana Andrade, Founder & Managing Director at RD Privacy and Data Protection Officer (DPO) for Biopharma and Life Sciences. They talk about the current state of data protection regulations and how enterprises can innovate responsibly.

In the recent episode of The Chain Reaction podcast, Nour AlSaleh, Founder and CEO of Veragence Pharma Consultancy, sat down with host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io and EM360Tech. AlSaleh shares her expertise on maintaining data integrity in this new era of AI and changing policies.

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

In the recent episode of the Digital Pulse podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, sat down with Lara Masad, an AI and Data Innovation independent consultant, to clarify the key distinctions in AI and machine learning models. Furthermore, Masad explains how pharmaceutical companies benefit from using AI models.

Trisha Pillay speaks with Judit Mora, CEO of Nuumad, on Digital Pulse discussing pharmacy innovation, market access barriers, and new models for faster patient access to healthcare.

Exclusive Pharmatica Content

Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.

Nicole Dale

Maximise Pharma Innovation With Quality-by-Design

Quality-by-Design pharmaceutical innovation in action, featuring tablet formulation analysis, molecular modelling, and digital quality systems supporting efficient drug development and manufacturing.

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Nicole Dale

Digital Twins in Clinical Trials: Simulating Success Before Enrolment

Digital twins in clinical trials simulate patient outcomes to reduce risk and accelerate timelines. Learn how sponsors use them for predictive trial design.

Trisha Pillay

How Pharmacy Innovation Is Changing Healthcare Delivery

Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.

Trisha Pillay

The Role of Regulatory Leadership in Healthcare

Regulatory leadership is no longer just compliance. In this episode of Chain Reaction, Dineshree Naiker explains why early regulatory strategy, supply chain governance, and value-based thinking are critical to improving patient access and healthcare outcomes.

Trisha Pillay

Healthcare Supply Chains in Africa: Lessons from COVID-19

COVID-19 exposed major weaknesses in pharmaceutical supply chains. In this episode of Chain Reaction, Trisha Pillay and Émile Malan explore how AI, regulatory reform, and local manufacturing could strengthen healthcare resilience.

Nicole Dale

Phenotypic Drug Discovery: Beyond the Target

Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.

Nicole Dale

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Nicole Dale

Precision Logistics to Speed Up Clinical Trials

Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.

Nicole Dale

Cell Therapy for Solid Tumours: Current Challenges and New Advances

Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.

Nicole Dale

Designing Decentralised Clinical Trials for Patient Diversity

A graphic banner for "Pharmatica" on DCT and Patient Diversity displaying a healthcare clinical trial theme. Left & Center: A realistic photo of an older Black woman sitting in a medical office, smiling and conversing with a female healthcare provider who is wearing a white lab coat and stethoscope.

Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.

Nicole Dale

Why Precision Alone Isn't Enough in Oncology Drug Discovery

Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.

Nicole Dale

Select the Right Data Collection Method for Real-World Evidence

Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.